Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Roberto Girelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5521-6218; OpenAlex author ID A5108027255. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 4 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 19

  1. The Role of a "Conservative" Resection Strategy After Neoadjuvant Treatment for Borderline/Locally Advanced PDAC with Arterial Involvement: A Single-Centre Ret… Co-author DOI 10.3390/cancers18050830↗
  2. Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers16234106↗
  3. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.02.005↗
  4. US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience. Co-author DOI 10.1055/a-1178-0474↗
  5. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  6. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Last author DOI 10.1016/j.pan.2021.06.005↗
  7. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… Co-author DOI 10.1097/as9.0000000000000087↗
  8. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Lite… Co-author DOI 10.3390/cancers11070981↗
  9. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Co-author DOI 10.1007/s00423-017-1627-0↗
  10. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Last author DOI 10.1007/s00464-018-6217-x↗
  11. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Co-author DOI 10.1016/j.pan.2017.09.008↗
  12. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Co-author DOI 10.1245/s10434-017-5885-4↗
  13. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging. Co-author DOI 10.4103/eus.eus_67_17↗
  14. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer. Co-author DOI 10.1007/s13304-016-0385-9↗
  15. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Co-author DOI 10.1155/2016/4508376↗
  16. Percutaneous ablation of pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i44.9661↗
  17. Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.085↗
  18. Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center. First author DOI 10.1007/s00534-013-0613-3↗
  19. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. First author DOI 10.1002/bjs.8789↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isabella M. Frigerio · 15 shared papers, 2012–2026 · strength 1.50
  2. Alessandro Giardino · 14 shared papers, 2012–2026 · strength 1.38
  3. Giovanni Butturini · 10 shared papers, 2016–2026 · strength 1.14
  4. Paolo Regi · 9 shared papers, 2013–2026 · strength 1.07
  5. Filippo Scopelliti · 8 shared papers, 2017–2026 · strength 1.03
  6. Claudio Bassi · 13 shared papers, 2012–2022 · strength 0.94
  7. Roberto Salvia · 12 shared papers, 2012–2022 · strength 0.91
  8. Salvatore Paiella · 9 shared papers, 2016–2022 · strength 0.67
  9. Mirko D’Onofrio · 8 shared papers, 2016–2022 · strength 0.61
  10. Giuseppe Malleo · 5 shared papers, 2017–2022 · strength 0.45
  11. Paolo Pederzoli · 4 shared papers, 2016–2026 · strength 0.44
  12. Gaya Spolverato · 2 shared papers, 2023–2024 · strength 0.35
  13. Quoc Riccardo Bao · 2 shared papers, 2023–2024 · strength 0.35
  14. Riccardo De Robertis Lombardi · 4 shared papers, 2016–2022 · strength 0.32
  15. Erica Pizzocaro · 1 shared paper, 2026 · strength 0.25
  16. Roberta Vella · 1 shared paper, 2026 · strength 0.25
  17. Matteo De Pastena · 2 shared papers, 2018–2022 · strength 0.20
  18. Darío Gregori · 1 shared paper, 2024 · strength 0.19
  19. Roberto Bianco · 2 shared papers, 2019–2021 · strength 0.18
  20. Marzia Tripepi · 1 shared paper, 2023 · strength 0.16
  21. Alessandro Beleù · 1 shared paper, 2022 · strength 0.15
  22. Alessandro Esposito · 1 shared paper, 2022 · strength 0.13
  23. Andrea Mambrini · 2 shared papers, 2012–2021 · strength 0.13
  24. Maurizio Cantore · 2 shared papers, 2012–2021 · strength 0.13
  25. Giammaria Fiorentini · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.